# Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma

> **NCT03619239** · PHASE1 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Newly Diagnosed Glioblastoma

## Interventions

- **DRUG:** GX-I7

## Key facts

- **NCT ID:** NCT03619239
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-20
- **Primary completion:** 2020-09-25
- **Final completion:** 2020-09-25
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03619239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03619239, "Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03619239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*